SAN DIEGO, Sept. 11, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Yuichi Iwaki, M.D., Ph.D., its President and Chief Executive Officer, has established a stock purchase plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 and MediciNova’s insider trading policy. Dr. Iwaki has served as MediciNova’s Chief Executive Officer since March 2006 and as a director since September 2000.
